Amylyx Pharmaceuticals, Inc. (AMLX) – What Are Analysts Saying About This Stock?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $40.71.

Several equities analysts have issued reports on the company. Robert W. Baird boosted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Citigroup raised their price objective on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Finally, Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 9,536 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider owned 190,838 shares of the company’s stock, valued at $6,194,601.48. This represents a 4.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares of the company’s stock, valued at approximately $21,685,803.70. This represents a 3.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 60,374 shares of company stock valued at $1,815,257. 10.90% of the stock is currently owned by company insiders.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $158,534,000. Jupiter Topco LLC bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth $94,014,000. Siren L.L.C. acquired a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at $17,097,000. Alyeska Investment Group L.P. acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $18,912,000. Finally, Almitas Capital LLC acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $17,509,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $28.86 on Tuesday. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -20.18 and a beta of -0.10. The business’s 50-day moving average is $30.89 and its 200-day moving average is $20.05. Amylyx Pharmaceuticals has a 1 year low of $10.83 and a 1 year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Analysts anticipate that Amylyx Pharmaceuticals will post -1.48 EPS for the current year.

About Amylyx Pharmaceuticals